CN116064313A - Application of lactobacillus plantarum CCFM1281 in relieving exercise fatigue - Google Patents
Application of lactobacillus plantarum CCFM1281 in relieving exercise fatigue Download PDFInfo
- Publication number
- CN116064313A CN116064313A CN202211338232.9A CN202211338232A CN116064313A CN 116064313 A CN116064313 A CN 116064313A CN 202211338232 A CN202211338232 A CN 202211338232A CN 116064313 A CN116064313 A CN 116064313A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- ccfm1281
- exercise
- fatigue
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 86
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 86
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 86
- 235000013365 dairy product Nutrition 0.000 claims abstract description 13
- 244000005700 microbiome Species 0.000 claims abstract description 12
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims abstract description 10
- 241000194020 Streptococcus thermophilus Species 0.000 claims abstract description 10
- 239000002207 metabolite Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 31
- 239000000843 powder Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 4
- 235000013376 functional food Nutrition 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 238000009629 microbiological culture Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 235000021107 fermented food Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 57
- 210000002966 serum Anatomy 0.000 abstract description 40
- 230000000694 effects Effects 0.000 abstract description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 17
- 239000008103 glucose Substances 0.000 abstract description 17
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 abstract description 13
- 102000003855 L-lactate dehydrogenase Human genes 0.000 abstract description 12
- 108700023483 L-lactate dehydrogenases Proteins 0.000 abstract description 12
- 238000009825 accumulation Methods 0.000 abstract description 6
- 239000006041 probiotic Substances 0.000 abstract description 6
- 235000018291 probiotics Nutrition 0.000 abstract description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 abstract description 4
- 230000004060 metabolic process Effects 0.000 abstract description 3
- 229910021529 ammonia Inorganic materials 0.000 abstract description 2
- 230000005856 abnormality Effects 0.000 abstract 1
- 230000004151 fermentation Effects 0.000 abstract 1
- 238000000855 fermentation Methods 0.000 abstract 1
- 238000003306 harvesting Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000000529 probiotic effect Effects 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
- 206010016256 fatigue Diseases 0.000 description 55
- 210000003205 muscle Anatomy 0.000 description 27
- 230000009182 swimming Effects 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 19
- 238000000034 method Methods 0.000 description 16
- 239000007788 liquid Substances 0.000 description 13
- 229920002527 Glycogen Polymers 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 229940096919 glycogen Drugs 0.000 description 12
- 235000020183 skimmed milk Nutrition 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 210000000663 muscle cell Anatomy 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000000386 athletic effect Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 244000017020 Ipomoea batatas Species 0.000 description 4
- 235000002678 Ipomoea batatas Nutrition 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- 108010073771 Soybean Proteins Proteins 0.000 description 4
- 108010046377 Whey Proteins Proteins 0.000 description 4
- 102000007544 Whey Proteins Human genes 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 230000037080 exercise endurance Effects 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000020185 raw untreated milk Nutrition 0.000 description 4
- 235000019710 soybean protein Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 235000021119 whey protein Nutrition 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000021001 fermented dairy product Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1315—Non-milk proteins or fats; Seeds, pulses, cereals or soja; Fatty acids, phospholipids, mono- or diglycerides or derivatives therefrom; Egg products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses an application of lactobacillus plantarum CCFM1281 in relieving exercise-induced fatigue, and belongs to the technical field of microorganisms. The lactobacillus plantarum CCFM1281 provided by the invention can increase the time of the mice to swim; reducing serum urea nitrogen level, relieving abnormality of ammonia metabolism in vivo, and reducing accumulation of metabolites; increasing myoglycogen levels; reducing serum lactate dehydrogenase activity, reducing tissue damage due to excessive exercise; increasing serum glucose levels ensures a sufficient energy substrate supply during exercise to harvest more energy. The lactobacillus plantarum 1281, the basic fermentation strain lactobacillus delbrueckii subspecies bulgaricus JCCC 0018 and streptococcus thermophilus JCCC 0019 are used for preparing the dairy product, and the obtained probiotic product can effectively relieve exercise fatigue from multiple aspects and has wide application prospect.
Description
Technical Field
The invention relates to application of lactobacillus plantarum CCFM1281 in relieving exercise-induced fatigue, and belongs to the technical field of microorganisms.
Background
Exercise fatigue refers to a physiological phenomenon in which exercise causes muscles to produce maximum contraction force or maximum output power to temporarily decrease. Since physical characterization of athletic fatigue is less obvious, most people are not aware of the serious effects of athletic fatigue, most athletes and physical workers are deeply harmed, and long-term fatigue can greatly affect their study, work and life. At present, the treatment of sports fatigue mostly adopts a method of taking sleep rest as a main part and taking dietary medicines as an auxiliary part, products aiming at more fatigue on the market comprise medicines, functional beverages, meal replacement powder and the like, but the products have more or less side effects, mainly exogenous physical changes caused by fatigue resistance, and have certain risks and crowd pertinence.
The gastrointestinal tract of the human body contains a number of commensal bacteria, known as microbiota, which benefit host health by digesting dietary components and eliminating pathogens. Probiotics are defined as "live microorganisms that when ingested in sufficient amounts, confer a beneficial health effect on the host", lactobacillus plantarum being one of the probiotics that has been shown to have a certain immunomodulating effect, inhibiting the growth of pathogenic bacteria, etc.
Along with the continuous development and scientific progress of the exercise industry in China, the endogenous alleviation of physical and mental fatigue in the exercise process through intestinal flora is important, along with the fact that dairy products become indispensable food in daily life of people, fermented dairy products are excellent carriers of probiotics, the probiotics capable of alleviating the exercise fatigue are found and applied to the fermented dairy products, and the fermented dairy products have great significance for social groups loving exercises.
In view of the above, it is necessary to find a lactobacillus plantarum strain capable of alleviating exercise-induced fatigue and applied to the development of dairy products.
Disclosure of Invention
A first object of the present invention is to provide Lactobacillus plantarum (Lactiplantibacillus plantarum) CCFM1281, deposited with the Guangdong province microorganism strain collection at 9/15 of 2022 under the accession number GDMCC No:62797.
it is a second object of the present invention to provide a composition comprising said lactobacillus plantarum CCFM 1281.
In one embodiment, the Lactobacillus plantarum CCFM1281 is present in an amount of 1X 10 or more 9 CFU/mL or ≡1X10. 9 CFU/g。
In one embodiment, the composition includes, but is not limited to, a microbial formulation, a functional food, or a dietary supplement.
In one embodiment, the composition contains a live strain, a dry strain, a strain metabolite, or an inactivated strain of the lactobacillus plantarum CCFM 1281.
In one embodiment, the composition is a dairy product that relieves exercise-induced fatigue.
In one embodiment, the dairy product is prepared from the lactobacillus plantarum (Lactiplantibacillus plantarum) CCFM1281, lactobacillus delbrueckii subspecies bulgaricus JMCC0018 and streptococcus thermophilus JMCC 0019; the lactobacillus delbrueckii subspecies bulgaricus JMCC0018 has been deposited in 2017 with the common microorganism strain collection of the China Committee for culture Collection of microorganisms, accession number: CGMCC No.14425; the streptococcus thermophilus JMCC0019 was deposited in 2017 at the China general microbiological culture Collection center, with the deposit number: CGMCC No.14426.
In one embodiment, the dairy product is further added with nutritional elements such as amino acids, minerals, and the like.
In one embodiment, the formulation of the dairy product comprises by mass: 80 parts of raw milk, 5 parts of glucose, 10 parts of soybean protein, 13 parts of casein, 10 parts of whey protein, 9 parts of oat, 20 parts of purple sweet potato, 0.2 part of vitamin, 0.05 part of Lactobacillus delbrueckii subspecies bulgaricus JCCC 0018, 0.6 part of streptococcus thermophilus JCCC 0019 and 1 part of lactobacillus plantarum CCFM 1281.
In one embodiment, the method of preparing the dairy product is as follows:
(1) Pasteurizing raw milk, adding soybean protein powder, casein powder, whey protein powder and glucose, and stirring thoroughly to obtain a mixture A;
(2) Homogenizing the mixture A to obtain a liquid mixture B;
(3) Adding oat, purple sweet potato and vitamin into the liquid mixture B, fully and uniformly stirring, and sterilizing to obtain a mixture C;
(4) Cooling the mixture C, adding lactobacillus delbrueckii subspecies bulgaricus JMCC0018, streptococcus thermophilus JMCC0019 and lactobacillus plantarum CCFM1281 to obtain a liquid mixture D, fully stirring, fermenting until the pH value is 4.5-4.7, stopping to obtain a liquid mixture E, stirring, demulsification, cooling to below 4 ℃, and after-ripening for 11-13 h.
The third object of the invention is to provide an application of the lactobacillus plantarum CCFM1281 in preparing medicines or health-care products for preventing and/or relieving sports fatigue.
In one embodiment, the application includes, but is not limited to, at least one of the following:
(1) Improving exercise tolerance of the mammal;
(2) Reducing the serum urea nitrogen level elevation of the mammal caused by exercise;
(3) Increasing muscle glycogen levels in the mammal resulting from exercise;
(4) Increasing serum glucose levels in the mammal due to exercise;
(5) Reducing the serum lactate dehydrogenase level elevation of the mammal caused by exercise.
In one embodiment, the mammal includes, but is not limited to, a human.
In one embodiment, the medicine or health product is a plurality of solid preparation forms such as capsules, tablets, granules or powder containing lactobacillus plantarum CCFM1281 and auxiliary materials.
The invention also provides application of the lactobacillus plantarum CCFM1281 in preparation of fermented food.
The beneficial effects are that: the lactobacillus plantarum CCFM1281 can improve the exhaustion swimming time of a tired mouse and enhance exercise endurance; can reduce serum urea nitrogen level of tired mice and reduce excessive accumulation of metabolites; can increase the storage capacity of the muscle glycogen of the fatigued mice and increase the accumulation of energy substances; can increase the glucose level of serum of a fatigued mouse and maintain the whole energy supply in the exercise process; can reduce the level of lactate dehydrogenase in serum of tired mice and reduce exercise injury caused by high-strength exercise. The lactobacillus plantarum CCFM1281 can comprehensively relieve exercise fatigue by relieving various aspects such as energy consumption, metabolite accumulation, tissue injury and the like, lightens the damage degree of muscles, and has wide application prospect in the field of functional foods by using the lactobacillus plantarum CCFM1281 for preparing dairy products.
Preservation of biological materials
Lactobacillus plantarum (Lactiplantibacillus plantarum) CCFM1281, classified under Lactiplantibacillus plantarum, was deposited in the Guangdong province microorganism strain collection at 9/15 of 2022 at floor 5, accession number GDMCC No:62797.
drawings
FIG. 1 shows the swimming time of different groups of mice;
FIG. 2 is the serum urea nitrogen concentration of different groups of mice;
FIG. 3 is the muscle glycogen content of different groups of mice;
FIG. 4 is serum glucose concentration of different groups of mice;
FIG. 5 is serum lactate dehydrogenase activity of different groups of mice;
FIG. 6 is serum lactate concentration of mice of different groups;
FIG. 7 is the change in body weight of different groups of mice;
FIG. 8 is a graph showing muscle damage in different groups of mice;
wherein, P <0.05, P <0.01, all groups compared to the fatigue group.
Detailed Description
Example 1 screening of Lactobacillus plantarum CCFM1281 and preparation of bacterial suspension
Isolation and screening of Lactobacillus
(1) Fecal samples were collected from 30 year old healthy women. Is spread in MRS medium, and cultured in anaerobic incubator (N 2 :CO 2 :H 2 =80:10:10), and then the enriched samples were gradient diluted and coated on MRS solid plates, the gradients were 10 respectively -1 、10 -2 、10 -3 、10 -4 、10 -5 、10 -6 、10 -7 、10 -8 All are placed in an anaerobic incubator for culturing for 48 hours.
(2) Plates of appropriate dilution gradient were selected, and all eligible colonies were picked with an inoculating loop according to the color, size, edge shape, etc. of the colonies and streaked on MRS solid plates for purification.
(3) The single colony is cultured in liquid MRS culture solution for 24 hours, then gram staining is carried out, and gram positive bacteria are selected for subsequent tests.
(4) Selecting 5 gram-positive bacteria from the step (3), respectively carrying out streak purification on an MRS solid plate again, and culturing in an anaerobic incubator for 48 hours to obtain pure culture strains.
(5) The pure culture strain obtained in the step (4) is mixed with sterile glycerol and placed in a strain preservation tube for preservation at the temperature of minus 80 ℃.
Molecular biological identification of Lactobacillus
(1) Performing PCR amplification and identification on the single colony obtained after separation and purification by using 16S rDNA bacteria, wherein the 16S rDNA sequence is determined as shown in SEQ ID NO.1, and the identification unit is as follows: su Jin Weizhi biotechnology limited. Identification result: the strain is Lactobacillus plantarum, presumably Lactobacillus plantarum.
(2) The identified strain was designated as Lactobacillus plantarum CCFM1281 and was stored at-80℃for further use.
Preparation of bacterial suspension
Culturing Lactobacillus plantarum CCFM1281 in MRS medium at 37deg.C for 12 time, collecting culture solution, centrifuging to collect bacterial mud, washing with physiological saline, and re-suspending with 10% (100 g/L) skimmed milk to obtain 1.02X10-g extract 9 CFU/mL bacterial suspension.
Example 2: lactobacillus plantarum CCFM1281 has good tolerance to simulated gastrointestinal fluids
Inoculating Lactobacillus plantarum CCFM1281 with 2% inoculation volume fraction into MRS liquid culture medium, culturing in 37 deg.C constant temperature incubator for 12 hr, performing plate count with different concentration gradients, and processing to obtain viable bacteria concentration of 1×10 10 CFU/mL broth.
Taking 0.5ml of bacterial liquid, centrifuging for 2min at 6000r/min, removing supernatant, washing precipitate with physiological saline for 2 times, re-suspending the obtained bacterial sludge into 4.5ml of artificial gastric juice (physiological saline containing 3g/L pepsin and pH=3.0), uniformly mixing, culturing in a constant temperature incubator at 37 ℃, sampling at 0h and 2h respectively, performing plate colony counting by casting culture with MRS agar culture medium, measuring the number of viable bacteria, calculating the survival rate of the viable bacteria, and performing three experiments in parallel.
Centrifuging 0.5ml of bacterial liquid at 6000r/min for 2min, removing supernatant, washing precipitate with physiological saline for 2 times, re-suspending the obtained bacterial mud into 4.5ml of artificial intestinal liquid (physiological saline containing trypsin 1g/L, bile salt 0.3% and pH=8.0), mixing, culturing in a constant temperature incubator at 37deg.C, sampling at 0 hr, 2 hr, and 4 hr respectively, performing plate colony counting with MRS agar culture medium, measuring viable count and calculating survival rate, and performing three experiments
The survival rate (%) was calculated as the ratio of the number of viable bacteria at the time of sampling to the number of viable bacteria at the time of 0h in the culture solution.
The results are shown in Table 1, the Lactobacillus plantarum CCFM1281 has better tolerance in artificial simulated gastric and intestinal fluids, the survival rate in the process of tolerating gastric and intestinal fluids for 2 hours is more than 95%, and the survival rate in the process of tolerating intestinal fluids for 4 hours is more than 90%, thus having better probiotics characteristics.
TABLE 1 tolerance of Lactobacillus plantarum CCFM1281 in artificially simulated gastrointestinal fluids
Example 3: animal experiment of the action of Lactobacillus plantarum CCFM1281 on the relief of exercise-induced fatigue
Preparation of gastric lavage strain: taking out the identified and preserved lactobacillus plantarum CCFM1281, lactobacillus plantarum FXJWS11M2 and lactobacillus plantarum ATCC10241 in the fungus library, marking out an MRS flat plate, culturing for 48 hours at 37 ℃, and picking out single colony for continuous liquid activation twice to obtain seed liquid; the seed liquid is centrifuged at high speed to obtain bacterial mud, the bacterial mud is redissolved in 10% of skimmed milk, the viable count in the skimmed milk is calculated by using a plate counting method, and three gastric lavage reagents are prepared by diluting 10% of skimmed milk by a certain degree: the concentration is 1.02X10 9 CFU/mL of 10% skim milk of Lactobacillus plantarum CCFM1281 at a concentration of 1.02X10 9 CFU/mL 10% skim milk of Lactobacillus plantarum FXJWS11M2 at a concentration of 1.02X10 9 CFU/mL 10% skim milk of Lactobacillus plantarum ATCC 10241. The above-mentioned Lactobacillus plantarum CCFM1281 is derived from example 1; lactobacillus plantarum FXJWS11M2 is disclosed in "Mao B, yin R, li X, cui S, zhang H, zhao J, chen W.complex Genomic Analysis of Lactiplantibacillus plantarum Isolated from Different Niches. Genes (Basel). 2021Feb 8;12 (2) 241.doi:10.3390/genes12020241.PMID:33567604; PMCID: PMC7914981 "; lactobacillus plantarum ATCC10241 was purchased from ATCC.
Experimental animals were purchased from 40 healthy male ICR mice, provided the mice with free and sufficient moisture and feed, kept in specific barriers, and maintained at the appropriate temperature and humidity for 12 hours each in the light and dark. All experimental mice were randomized into 5 groups after one week of acclimation, blank, fatigue, CCFM1281, FXJWS11M2, ATCC 10241. The fatigue group and the three intervention groups were subjected to a load swimming model test for six weeks, and weekly weight changes of the mice were recorded.
Mice in the blank group were filled with 200 μl of 10% skim milk reconstituted with ultrapure water daily; the fatigued mice were filled with 200 μl of 10% skim milk reconstituted with ultrapure water daily; CCFM1281 intervention group was perfused 200. Mu.L daily with 1.02X10 g concentration 9 CFU/mL 10% skim milk of Lactobacillus plantarum CCFM 1281; FXJWS11M 2-mediated group was gavaged 200. Mu.L daily with 1.02X10 concentration 9 CFU/mL 10% skim milk of Lactobacillus plantarum FXJWS11M2, ATCC10241 intervention group was gavaged 200. Mu.L daily with 1.02X10 concentration 9 CFU/mL 10% skim milk of Lactobacillus plantarum ATCC 10241.
After six weeks of modeling, the exercise endurance of all mice was measured, and the behavioural study was performed using the forced swimming time test: all mice are swim by adopting a tail load mode, the winding tightness is proper, the total weight is 5% of the weight, and the mice are independently arranged in a swimming box with the water depth of 50cm and the water temperature of 25+/-1 ℃. Starting timing from the entry of the mice into the water tank, when the mice swim to the water surface for 3 consecutive times, each time exceeding 7s, the mice are regarded as exhaustion, and the time of swimming exhausted is recorded. The results are shown in Table 2.
TABLE 2 animal experimental behavioral indicators
| Group of | Swimming time(s) of the exhaustion |
| Blank group | 828.333±295.663 |
| Fatigue group | 315±96.281 |
| CCFM1281 intervention group | 971.833±387.685 |
| FXJWS11M2 intervention group | 415.143±188.606 |
| ATCC10241 intervention group | 438.75±158.784 |
Note that: all values are expressed as mean±sd
The results show that: compared with a blank group, the load swimming modeling experiment obviously reduces the exhaustion swimming time of the mice in the fatigue group; compared with the fatigue group, the lactobacillus plantarum CCFM1281 intervention group can significantly increase the forced swimming time. This suggests that athletic fatigue can lead to a significant reduction in athletic endurance, while lactobacillus plantarum CCFM1281 can significantly improve the anti-fatigue ability and athletic endurance of mice; the improvement of the swimming time of the dragline is not obvious by FXJWS11M2 and ATCC10241 which are both lactobacillus plantarum, and the improvement of the swimming time of the dragline has no obvious influence on the exercise endurance of mice.
After the exercise endurance of all mice is detected, carrying out no-load swimming on all mice in a water tank the next day, immediately taking eyeballs to obtain blood after swimming for 30 minutes, and carrying out sacrifice dissection by a cervical dislocation method, taking a whole blood sample, and freezing at-80 ℃; centrifuging the rest blood sample at 3500r/min for 15 min, collecting supernatant, and freezing at-80deg.C for serum index analysis; the tissue samples (muscle and liver) are frozen in liquid nitrogen after being subpackaged and transferred to-80 ℃ for frozen storage for tissue index analysis; the right leg gastrocnemius muscle was taken and stored in 4% paraformaldehyde and placed in the dark for slice analysis.
Example 4: animal experiments of the remission effect of lactobacillus plantarum CCFM1281 on exercise-induced fatigue: analysis of serum lactic acid and serum urea nitrogen content
Animal model construction the serum urea nitrogen and serum lactate levels were measured in the serum samples of all mice after 30 minutes of non-load swimming as in example 3. The determination of serum urea nitrogen and serum lactic acid was performed according to the kit method.
As shown in table 3, the load swimming modeling experiment significantly increased serum urea nitrogen in the mice of the fatigue group compared to the blank group; the serum urea nitrogen was significantly reduced in the lactobacillus plantarum CCFM 1281-interfered group compared to the fatigued group. This suggests that exercise fatigue can lead to excessive accumulation of serum urea nitrogen, while lactobacillus plantarum CCFM1281 can effectively combat the disorder of ammonia metabolism caused by exercise fatigue, thereby effectively relieving exercise fatigue; the lactobacillus plantarum FXJWS11M2 intervention group and lactobacillus plantarum ATCC10241 had little effect on serum urea nitrogen content relative to the fatigue group.
While for serum lactate levels, there was no significant variability between groups, although there was a trend to decrease serum lactate in the CCFM 1281-interfered group mice.
TABLE 3 animal experiments blood lactic acid, blood urea nitrogen index analysis
| Group of | Serum lactic acid (mmol/L) | Serum urea nitrogen (mmol/L) |
| Blank group | 10.258±1.068 | 15.296±1.084 |
| Fatigue group | 10.521±1.637 | 18.396±2.965 |
| CCFM1281 interventionGroup of | 8.74±1.877 | 14.387±1.391 |
| FXJWS11M2 intervention group | 10.512±3.271 | 21.777±3.177 |
| ATCC10241 intervention group | 11.637±2.44 | 18.371±1.953 |
Example 5: animal experiments of the remission effect of lactobacillus plantarum CCFM1281 on exercise-induced fatigue: analysis of glycogen content in muscle tissue
Animal model construction As in example 3, glycogen levels in muscle tissue samples of mice after 30 minutes of swimming without load were measured and muscle glycogen levels were measured according to the kit method.
As shown in table 4, the load swimming modeling experiment significantly reduced the muscle glycogen levels in the mice of the fatigue group compared to the blank group; the lactobacillus plantarum CCFM 1281-interfered group mice had significantly elevated muscle glycogen levels compared to the fatigued group. This suggests that anaerobic metabolism of muscle during exercise-induced fatigue leads to excessive consumption of muscle glycogen with a greatly reduced accumulation; the lactobacillus plantarum CCFM1281 can effectively increase energy reserve in muscles in the process of maintaining the same exercise intensity, so that exercise fatigue is effectively relieved; while FXJWS11M2 and ATCC10241, which are also lactobacillus plantarum, do not significantly affect the characterization of glycogen content on peripheral muscle tissue.
TABLE 4 muscle glycogen index of muscle tissue in animal experiments
| Group of | Myoglycogen (mg/g) |
| Blank group | 0.858±0.125 |
| Fatigue group | 0.656±0.091 |
| CCFM1281 intervention group | 0.909±0.212 |
| FXJWS11M2 intervention group | 0.704±0.184 |
| ATCC10241 intervention group | 0.649±0.071 |
Example 6: animal experiments of the remission effect of lactobacillus plantarum CCFM1281 on exercise-induced fatigue: serum lactate dehydrogenase Activity assay
Animal model construction the lactate dehydrogenase activity in the serum of mice after 30 minutes of swimming without load was measured as in example 3, and the measurement of the lactate dehydrogenase activity in the serum was performed according to the kit method.
As shown in table 5, compared with the blank group, the load swimming modeling experiment significantly increased the lactate dehydrogenase activity of the mice in the fatigue group; the lactobacillus plantarum CCFM1281 intervention group had significantly reduced lactate dehydrogenase activity compared to the fatigue group. This suggests that exercise fatigue may cause serious damage to the muscle tissue of mice and the like, resulting in excessive lactate dehydrogenase entering the blood; the lactobacillus plantarum CCFM1281 can reduce the damage to muscles of mice in the exercise process, so that the exercise fatigue is effectively relieved. Whereas the FXJWS11M2 of Lactobacillus plantarum and Lactobacillus plantarum ATCC10241 have no significant effect on the serum phenotype index caused by the damage of muscle tissue due to exercise-induced fatigue.
TABLE 5 serum lactate dehydrogenase index for animal experiments
| Group of | Lactate dehydrogenase (U/L) |
| Blank group | 2948.646±189.671 |
| Fatigue group | 3270.588±259.494 |
| CCFM1281 intervention group | 2433.551±395.318 |
| FXJWS11M2 intervention group | 2801.12±479.504 |
| ATCC10241 intervention group | 3074.254±454.407 |
Example 7: animal experiments of the remission effect of lactobacillus plantarum CCFM1281 on exercise-induced fatigue: serum glucose level analysis
Animal model construction the glucose level in the serum of mice after 30 minutes of swimming without load was measured as in example 3 and the measurement of the glucose level in the serum was performed according to the kit method.
As shown in table 6, the weight-bearing swimming modeling experiment resulted in a trend of lower, but not significant, serum glucose levels in the fatigued mice compared to the blank mice; the glucose levels were significantly elevated in the lactobacillus plantarum CCFM1281 intervention group compared to the fatigue group. This suggests that exercise fatigue reduces glucose supply during exercise in mice and overall energy supply is reduced; the lactobacillus plantarum CCFM1281 can enable the muscle tissue of the mice to obtain sufficient glucose in the exercise process, and reduce the loss of hepatic glycogen and myoglycogen, thereby effectively relieving exercise fatigue. While FXJWS11M2 and ATCC10241, which are also lactobacillus plantarum, had no significant effect on serum glucose levels.
TABLE 6 serum glucose index for animal experiments
Example 8: animal experiments of the remission effect of lactobacillus plantarum CCFM1281 on exercise-induced fatigue: analysis of weight change in mice
Animal model construction the mice were tested weekly for weight change as in example 3. As shown in fig. 7, the weight-bearing swimming modeling experiment reduced the rate of increase in weight of the mice in the fatigue group compared to the blank group, but did not adversely affect the health of the mice; the weight changes of the Lactobacillus plantarum CCFM1281 intervention mice, lactobacillus plantarum FXJWS11M2 intervention mice and Lactobacillus plantarum ATCC10241 intervention mice are all between the fatigue group and the blank group, and the difference is not obvious. This suggests that exercise-induced fatigue tends to thin mice, slowing weight gain during growth; the lactobacillus plantarum has little effect on the whole body weight change of mice, and the lactobacillus plantarum CCFM1281 cannot reverse the body weight change caused by exercise fatigue.
Example 9: animal experiments of the remission effect of lactobacillus plantarum CCFM1281 on exercise-induced fatigue: pathological section analysis of muscle tissue
According to example 3 of the present invention, to evaluate whether lactobacillus plantarum CCFM1281 has a pathologically adverse effect on muscle tissue, gastrocnemius muscle in a muscle tissue sample was taken for pathological section analysis.
As shown in fig. 8, the calf muscle disease of mice in the blank group shows slight difference in size of muscle cells, and the muscle cells are arranged in a polygonal shape, each muscle cell has a plurality of muscle cell nuclei, the muscle nuclei are positioned under the myomembrane, and the whole slice has no obvious inflammatory cell infiltration phenomenon; the gastrocnemius of the mice in the fatigue group is characterized by partial white necrosis of muscle cells, obvious swelling and atrophy, large and more cracks among cells, and obvious serious inflammatory cell infiltration; compared with the tired group, the lactobacillus plantarum CCFM1281 intervening group mice gastrocnemius has relatively compact pathological manifestations of muscle arrangement, but still has larger gaps, a small amount of muscle cells have the phenomenon of whitening and cracking, and the histopathological structure is close to that of the mice gastrocnemius in the blank group. The lactobacillus plantarum CCFM1281 can effectively relieve the injury of sports fatigue to muscles.
Example 10: lactobacillus plantarum CCFM1281 used for preparing dairy product for relieving exercise fatigue
The formula comprises the following components: 80 parts of raw milk, 5 parts of glucose, 10 parts of soybean protein, 13 parts of casein, 10 parts of whey protein, 9 parts of oat, 20 parts of purple sweet potato, 0.2 part of vitamin, 0.05 part of Lactobacillus delbrueckii subspecies bulgaricus JCCC 0018, 0019.6 parts of streptococcus thermophilus JCCC 0019 and CCFM1281 parts of lactobacillus plantarum, wherein the concentration of each strain is 10 11 CFU/g; wherein lactobacillus delbrueckii subspecies bulgaricus JMCC0018 was deposited in 2017 with the common microorganism strain collection of the China Committee for culture Collection of microorganisms, accession number: CGMCC No.14425; streptococcus thermophilus JMCC0019 was deposited in 2017 with the China general microbiological culture Collection center, accession number: CGMCC No.14426.
The manufacturing process comprises the following steps:
(1) Pasteurizing raw milk at 89.5-90.5 ℃ for 14-16 s, cooling to 40-45 ℃, and adding soybean protein powder, casein powder, whey protein powder and glucose respectively, and fully and uniformly stirring to obtain a mixture A;
(2) Homogenizing the mixture A at 60-65 deg.c and 16-20 MPa to obtain liquid mixture B;
(3) Adding oat, purple sweet potato and vitamin into the mixture B, fully and uniformly stirring, and sterilizing at 94.5-95.5 ℃ for 298-302 s to obtain a mixture C;
(4) Cooling the mixture C to 36-38 ℃, adding activated Lactobacillus delbrueckii subspecies bulgaricus JCCC 0018, streptococcus thermophilus JCCC 0019 and Lactobacillus plantarum CCFM1281 to obtain a mixture D, fully stirring, fermenting until the pH value is 4.5-4.7, stopping to obtain a mixture E, stirring, demulsification, cooling to below 4 ℃, and after-ripening for 11-13 h. The effect of the dairy product was verified by the methods of examples 3 to 9, and the results showed that the obtained dairy product had an effect of relieving exercise-induced fatigue.
While the invention has been described with reference to the preferred embodiments, it is not limited thereto, and various changes and modifications can be made therein by those skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (10)
1. Lactobacillus plantarum (Lactiplantibacillus plantarum) CCFM1281, deposited with the microorganism strain collection, cantonese province, 9/15/2022, under the accession number GDMCC No:62797.
2. a composition comprising the lactobacillus plantarum CCFM1281 of claim 1.
3. The composition according to claim 2, wherein the amount of Lactobacillus plantarum CCFM1281 is not less than 1X 10 9 CFU/mL or ≡1X10. 9 CFU/g。
4. A composition according to claim 2 or 3, wherein the composition comprises, but is not limited to, a microbial preparation, a functional food or a dietary supplement.
5. The composition of claim 4, wherein the composition comprises a live strain, a dry strain, a strain metabolite, or an inactivated strain of the lactobacillus plantarum CCFM 1281.
6. A composition according to claim 2 or 3, characterized in that it is a dairy product comprising lactobacillus plantarum (Lactiplantibacillus plantarum) CCFM1281, lactobacillus delbrueckii subspecies bulgaricus JMCC0018 and streptococcus thermophilus JMCC 0019; the lactobacillus delbrueckii subspecies bulgaricus JMCC0018 has been deposited in 2017 with the common microorganism strain collection of the China Committee for culture Collection of microorganisms, accession number: CGMCC No.14425; the streptococcus thermophilus JMCC0019 was deposited in 2017 at the China general microbiological culture Collection center, with the deposit number: CGMCC No.14426.
7. Use of lactobacillus plantarum CCFM1281 according to claim 1 for the preparation of a medicament or health product for preventing and/or alleviating sports fatigue.
8. The use according to claim 7, wherein the pharmaceutical or nutraceutical product is a solid formulation comprising lactobacillus plantarum CCFM1281 and an adjuvant.
9. The use according to claim 8, wherein the solid formulation is a capsule, a tablet, a granule or a powder.
10. Use of lactobacillus plantarum CCFM1281 according to claim 1 for the preparation of a fermented food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211338232.9A CN116064313A (en) | 2022-10-28 | 2022-10-28 | Application of lactobacillus plantarum CCFM1281 in relieving exercise fatigue |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211338232.9A CN116064313A (en) | 2022-10-28 | 2022-10-28 | Application of lactobacillus plantarum CCFM1281 in relieving exercise fatigue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116064313A true CN116064313A (en) | 2023-05-05 |
Family
ID=86182789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211338232.9A Pending CN116064313A (en) | 2022-10-28 | 2022-10-28 | Application of lactobacillus plantarum CCFM1281 in relieving exercise fatigue |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116064313A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117100772A (en) * | 2023-09-20 | 2023-11-24 | 西南大学 | Application of Lactobacillus plantarum SHY21-2 in increasing endurance and relieving fatigue |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI583388B (en) * | 2016-08-24 | 2017-05-21 | 國立體育大學 | Use of lactobacillus plantarum for manufacturing anti-fatigue probiotic composition for improve exercise performance |
| CN107974420A (en) * | 2017-12-17 | 2018-05-01 | 石家庄君乐宝乳业有限公司 | Lactobacillus bulgaricus JMCC0018, its isolation and purification method and the application of high yield acetaldehyde |
| CN108004167A (en) * | 2017-12-17 | 2018-05-08 | 石家庄君乐宝乳业有限公司 | Streptococcus thermophilus JMCC0019, its isolation and purification method and the application of one plant of extracellular polysaccharide |
| CN109042881A (en) * | 2018-08-31 | 2018-12-21 | 石家庄君乐宝乳业有限公司 | Sports type fermented dairy product and preparation method |
| CN110559339A (en) * | 2019-08-01 | 2019-12-13 | 嘉兴市爵拓科技有限公司 | Probiotic formulations for promoting athletic performance |
-
2022
- 2022-10-28 CN CN202211338232.9A patent/CN116064313A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI583388B (en) * | 2016-08-24 | 2017-05-21 | 國立體育大學 | Use of lactobacillus plantarum for manufacturing anti-fatigue probiotic composition for improve exercise performance |
| US20180055893A1 (en) * | 2016-08-24 | 2018-03-01 | National Taiwan Sport University | Use of lactobacillus plantarum composition for manufacturing anti-fatigue probiotic composition for improve exercise performance |
| CN107974420A (en) * | 2017-12-17 | 2018-05-01 | 石家庄君乐宝乳业有限公司 | Lactobacillus bulgaricus JMCC0018, its isolation and purification method and the application of high yield acetaldehyde |
| CN108004167A (en) * | 2017-12-17 | 2018-05-08 | 石家庄君乐宝乳业有限公司 | Streptococcus thermophilus JMCC0019, its isolation and purification method and the application of one plant of extracellular polysaccharide |
| CN109042881A (en) * | 2018-08-31 | 2018-12-21 | 石家庄君乐宝乳业有限公司 | Sports type fermented dairy product and preparation method |
| CN110559339A (en) * | 2019-08-01 | 2019-12-13 | 嘉兴市爵拓科技有限公司 | Probiotic formulations for promoting athletic performance |
Non-Patent Citations (4)
| Title |
|---|
| YEH WL等: "Lactobacillus plantarum PL-02 Supplementation Combined With Resistance Training Improved Muscle Mass, Force, and Exercise Performance in Mice", 《FRONT NUTR》, 27 April 2022 (2022-04-27) * |
| YI-MING CHEN等: "Lactobacillus plantarum TWK10 Supplementation Improves Exercise Performance and Increases Muscle Mass in Mice", 《NUTRIENTS》, 7 April 2016 (2016-04-07) * |
| 潘春梅主编: "《微生态制剂生产及应用》", 30 September 2014, 北京：中国农业大学出版社, pages: 86 - 87 * |
| 陈怡珊等: "补充植物乳杆菌TWK10对运动表现与体组成的影响", 《第十五届益生菌与健康国际研讨会摘要集》, 19 August 2020 (2020-08-19) * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117100772A (en) * | 2023-09-20 | 2023-11-24 | 西南大学 | Application of Lactobacillus plantarum SHY21-2 in increasing endurance and relieving fatigue |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111254089B (en) | Lactobacillus plantarum with weight losing function and application thereof | |
| CN101068918B (en) | Lactobacillus rhamnosus with body-fat reducing activity and the foods containing them | |
| US9649347B2 (en) | Protective effects and application of a Lactobacillus rhamnosus on the alleviation of chronic alcoholic liver injury | |
| CN110835616B (en) | Active substance of lactobacillus paracasei GKS6, composition containing same and application of active substance in promoting longevity | |
| US20140363501A1 (en) | The protective effects and application of a Lactobacillus rhamnosus on the alleviation of chronic alcoholic liver injury | |
| CN109810912B (en) | Lactobacillus plantarum LH-511 and application thereof | |
| RU2758109C2 (en) | Bacterium lactobacillus rhamnosus for the treatment of, for example, bacterial vaginosis | |
| CN105567586A (en) | Lactobacillus plantarum having anti-diabetic function and application thereof | |
| CN110964653B (en) | Lactobacillus paracasei ET-22 capable of adjusting intestinal flora balance | |
| CN110564638A (en) | Lactobacillus reuteri with probiotic characteristics and application thereof | |
| CN110106119B (en) | Lactobacillus rhamnosus M9 separated from breast milk and application thereof | |
| TWI745648B (en) | Starter culture containing mixture of lactic acid bacteria strains, and fermented product prepared using such starter culture and use of this fermented product | |
| KR20200027855A (en) | Lactobacillus rhamnosus having anti-inflammatory activity and enhancing gut microbiota | |
| CN111676157A (en) | Composition based on lactobacillus plantarum and preparation method thereof | |
| CN114921363A (en) | Composite probiotics for inhibiting fat accumulation and application thereof | |
| CN116286551B (en) | Application of bifidobacterium longum subspecies infantis in regulating in-vivo fat metabolism, shaping, reducing fat and improving obesity | |
| CN106795482A (en) | Allow the lactobacillus composition of the juvenile growth of promotion humans and animals in the case of malnutrition | |
| CN114717129A (en) | Lactobacillus rhamnosus and application thereof in preventing and relieving constipation symptoms | |
| CN110257302B (en) | Screening method and application of lactobacillus strain with antioxidant capacity | |
| CN111714572A (en) | Lactobacillus plantarum-based probiotic tablet and preparation method thereof | |
| CN110835615B (en) | Active substance of bifidobacterium lactis GKK2, composition containing same and application of active substance and composition in promoting longevity | |
| CN116064313A (en) | Application of lactobacillus plantarum CCFM1281 in relieving exercise fatigue | |
| CN110577907A (en) | Bifidobacterium animalis and application thereof | |
| CN115992071A (en) | Lactobacillus plantarum CCFM1280 with athletic fatigue relieving function and application thereof | |
| CN115478036A (en) | Mucous membrane lactobacillus capable of relieving non-alcoholic fatty liver disease and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |